TY - JOUR
T1 - Prescription of Anticholinergic Drugs in Patients With Schizophrenia
T2 - Analysis of Antipsychotic Prescription Patterns and Hospital Characteristics
AU - Hori, Hikaru
AU - Yasui-Furukori, Norio
AU - Hasegawa, Naomi
AU - Iga, Jun Ichi
AU - Ochi, Shinichiro
AU - Ichihashi, Kayo
AU - Furihata, Ryuji
AU - Kyo, Yoshitaka
AU - Takaesu, Yoshikazu
AU - Tsuboi, Takashi
AU - Kodaka, Fumitoshi
AU - Onitsuka, Toshiaki
AU - Okada, Tsuyoshi
AU - Murata, Atsunobu
AU - Kashiwagi, Hiroko
AU - Iida, Hitoshi
AU - Hashimoto, Naoki
AU - Ohi, Kazutaka
AU - Yamada, Hisashi
AU - Ogasawara, Kazuyoshi
AU - Yasuda, Yuka
AU - Muraoka, Hiroyuki
AU - Usami, Masahide
AU - Numata, Shusuke
AU - Takeshima, Masahiro
AU - Yamagata, Hirotaka
AU - Nagasawa, Tatsuya
AU - Tagata, Hiromi
AU - Makinodan, Manabu
AU - Kido, Mikio
AU - Katsumoto, Eiichi
AU - Komatsu, Hiroshi
AU - Matsumoto, Junya
AU - Kubota, Chika
AU - Miura, Kenichiro
AU - Hishimoto, Akitoyo
AU - Watanabe, Koichiro
AU - Inada, Ken
AU - Kawasaki, Hiroaki
AU - Hashimoto, Ryota
N1 - Funding Information:
This study was supported by the Japan Agency for Medical Research and Development (AMED) under Grant Number JP 18dk0307060, the AMED under Grant Number JP 19dk0307083, the Health and Labor Science Research Grants (H29-Seishin-Ippan-001, 19GC1201), the Japanese Society of Neuropsychopharmacology, and the Japanese Society of Mood Disorders. The funders had no role in the study design, data collection and analyses, decision to publish, or preparation of the manuscript.
Publisher Copyright:
Copyright © 2022 Hori, Yasui-Furukori, Hasegawa, Iga, Ochi, Ichihashi, Furihata, Kyo, Takaesu, Tsuboi, Kodaka, Onitsuka, Okada, Murata, Kashiwagi, Iida, Hashimoto, Ohi, Yamada, Ogasawara, Yasuda, Muraoka, Usami, Numata, Takeshima, Yamagata, Nagasawa, Tagata, Makinodan, Kido, Katsumoto, Komatsu, Matsumoto, Kubota, Miura, Hishimoto, Watanabe, Inada, Kawasaki and Hashimoto.
PY - 2022/5/17
Y1 - 2022/5/17
N2 - In several clinical guidelines for schizophrenia, long-term use of anticholinergic drugs is not recommended. We investigated the characteristics of the use of anticholinergics in patients with schizophrenia by considering psychotropic prescription patterns and differences among hospitals. A cross-sectional, retrospective prescription survey at the time of discharge was conducted on 2027 patients with schizophrenia from 69 Japanese hospitals. We examined the relations among psychotropic drug prescriptions regarding anticholinergic prescription. We divided the hospitals into three groups—low rate group (LG), medium rate group (MG), and high rate group (HG)—according to their anticholinergic prescription rates, and analyzed the relationship between anticholinergic prescription rates and antipsychotic prescription. Anticholinergic drugs were prescribed to 618 patients (30.5%), and the prescription rates were significantly higher for high antipsychotic doses, antipsychotic polypharmacy, and first-generation antipsychotics (FGAs) use. The anticholinergic prescription rate varied considerably among hospitals, ranging from 0 to 66.7%, and it was significantly higher in patients with antipsychotic monotherapy, antipsychotic polypharmacy, and normal and high doses of antipsychotics in HG than in those LG and MG. The anticholinergics prescription rate in patients with second-generation antipsychotic monotherapy in HG was also significantly higher than in those LG and MG; however, the difference was no longer significant in patients with FGA monotherapy. Conclusively, in addition to high antipsychotic doses, antipsychotic polypharmacy, and FGA use, hospital characteristics influence the prescribing of anticholinergic drugs.
AB - In several clinical guidelines for schizophrenia, long-term use of anticholinergic drugs is not recommended. We investigated the characteristics of the use of anticholinergics in patients with schizophrenia by considering psychotropic prescription patterns and differences among hospitals. A cross-sectional, retrospective prescription survey at the time of discharge was conducted on 2027 patients with schizophrenia from 69 Japanese hospitals. We examined the relations among psychotropic drug prescriptions regarding anticholinergic prescription. We divided the hospitals into three groups—low rate group (LG), medium rate group (MG), and high rate group (HG)—according to their anticholinergic prescription rates, and analyzed the relationship between anticholinergic prescription rates and antipsychotic prescription. Anticholinergic drugs were prescribed to 618 patients (30.5%), and the prescription rates were significantly higher for high antipsychotic doses, antipsychotic polypharmacy, and first-generation antipsychotics (FGAs) use. The anticholinergic prescription rate varied considerably among hospitals, ranging from 0 to 66.7%, and it was significantly higher in patients with antipsychotic monotherapy, antipsychotic polypharmacy, and normal and high doses of antipsychotics in HG than in those LG and MG. The anticholinergics prescription rate in patients with second-generation antipsychotic monotherapy in HG was also significantly higher than in those LG and MG; however, the difference was no longer significant in patients with FGA monotherapy. Conclusively, in addition to high antipsychotic doses, antipsychotic polypharmacy, and FGA use, hospital characteristics influence the prescribing of anticholinergic drugs.
UR - http://www.scopus.com/inward/record.url?scp=85131552857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131552857&partnerID=8YFLogxK
U2 - 10.3389/fpsyt.2022.823826
DO - 10.3389/fpsyt.2022.823826
M3 - Article
AN - SCOPUS:85131552857
SN - 1664-0640
VL - 13
JO - Frontiers in Psychiatry
JF - Frontiers in Psychiatry
M1 - 823826
ER -
